Komipharm

What Komipharm does

Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health and pharmaceutical company founded in 1972 (originally as Komilab) and headquartered in Siheung-Si, Gyeonggi-Do. The company operates two divisions: an Animal Health division that manufactures veterinary vaccines (including the PRO-VAC series for swine, poultry, and bovine), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers under Korean Veterinary Good Manufacturing Practice (KVGMP) standards; and a Pharmaceutical division developing human therapeutics anchored by the proprietary anticancer candidate KML001 (sodium metaarsenite), a telomere/telomerase-targeting agent with published Phase I clinical trial data.

The company generates revenue through one-time sales of veterinary products distributed domestically via a network of over 130 Korean distribution agents and internationally via direct exports to 27 countries. A second revenue stream comes from per-test fees charged by KRSL (Komipharm Rabies Serology Laboratory), which performs WOAH/ANSES-certified rabies neutralization antibody testing for international pet travel, with veterinary hospitals registering clients and submitting samples through an online portal. R&D is run from a Central Research Institute (established 1998) with cooperative research networks spanning 8 domestic and 10 overseas institutes in the US and Europe. Manufacturing is conducted at two plants in Yesan-Gun, Chungcheongnam-Do and Cheongwon-Gun, Chungcheongbuk-Do.

The go-to-market model is hybrid: domestically, channel partners (130+ distributors) supply veterinary hospitals and livestock farmers; internationally, direct sales with multilingual support teams (English, Chinese, Russian, Spanish) engage foreign customers through exhibitions and seminars. KOSDAQ listing since 2001 mandates formal IR disclosures, with reported sales of KRW 349.9B (2018), KRW 362.9B (2019), and KRW 380.2B (2020). Customer concentration risk is dispersed across many small veterinary hospitals and livestock farmers in both domestic and export markets, with no single dominant customer identified in the dataset.

Name

Komipharm

Legal name

Komipharm International Co., Ltd.

Website

https://komipharm.co.kr

Company type

Public

Founded year

1972

Operating status

Operating

Headcount range

101–250 employees

Short description

Komipharm International Co., Ltd. is a South Korea-based, KOSDAQ-listed animal health pharmaceutical company that develops, manufactures, and exports veterinary vaccines, antibiotics, and supplements for livestock and companion animals across 27 countries, and operates a WOAH-certified rabies serology testing laboratory.

Ownership category

akta.pro rank

Product category

Animal Health / Veterinary Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Veterinary Services (54194)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary vaccines
• Animal health products
• Rabies serology testing
• Livestock pharmaceuticals
• Anticancer drug development

Headquarters

HQ city

Siheungodong

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Veterinary Pharmaceuticals and Vaccines: Komipharm generates revenue primarily from the manufacture and sale of veterinary pharmaceuticals including vaccines (swine, avian, bovine, companion animal), chemical preparations, antibiotics, nutritional supplements, and metabolic/immune enhancers for livestock, aquaculture, and companion animals. Products are sold domestically through a network of 130+ distributors and exported to 27 countries globally.
2. Human Anti-Cancer Drug Development: Revenue from the development and potential commercialization of novel anti-cancer drug candidates including KML001 (sodium metaarsenite), focused on therapeutic agents for cancer pain and autoimmune diseases based on anticancer drug platforms.
3. Rabies Serology Laboratory Services (KRSL): KRSL provides rabies neutralization antibody testing services for international pet travel certification. Testing is conducted via veterinary hospital registration through the KRSL online portal, with sample collection at animal hospitals, laboratory testing at Komipharm, and results/certificates delivered by post or courier. Fees are charged per test.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Komipharm manufactures and sells veterinary vaccines (PRO-VAC series), antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock (swine, poultry, bovine), aquaculture, and companion animals under KVGMP standards. The company also operates KRSL, a WOAH/ANSES-certified rabies neutralization antibody testing laboratory serving international pet travel certification, and maintains a pharmaceutical division developing novel anticancer drug candidates including KML001 (sodium metaarsenite).

Product overview

Komipharm International Co., Ltd. operates two main business divisions: Animal Health and Pharmaceutical. The Animal Health division produces a comprehensive range of veterinary products including vaccine preparations (PRO-VAC series), chemical preparations, and aquaculture products for swine, poultry, bovine, and companion animals. The company also operates KRSL (Komipharm Rabies Serology Laboratory), an officially certified rabies antibody testing center. The Pharmaceutical division focuses on anticancer drug development, including the KML001 candidate. The company maintains a Central Research Institute for R&D activities and offers diagnostic services through its Disease Diagnosis Center.

Differentiator

Problem solved

Functional benefit

Brands

• KRSL: Komipharm Rabies Serology Laboratory - central research institute providing officially certified rabies neutralization antibody testing services, recognized by France's ANSES Nancy Laboratory as a standard rabies research institute under the World Animal Health Organization (WOAH).
• PRO-VAC
• KML001

Products and services

• PRO-VAC Series Veterinary Vaccines (Swine, Avian, Bovine) Comprehensive line of veterinary vaccines for prevention of economically significant livestock diseases including Classical Swine Fever, Newcastle Disease, Avian Influenza, Infectious Bovine Rhinotracheitis, BVD, Porcine Circovirus type 2, and Salmonella. Targeted at livestock farmers and veterinary hospitals in South Korea and across 27 export markets.
• RES-VAC (Swine Respiratory Complex Vaccine) Comprehensive swine respiratory vaccine effective against atrophic rhinitis, pasteurella pneumonia, mycoplasma pneumonia, pleuropneumonia, and Glasser's disease, designed to reduce vaccination frequency and pig stress. Targeted at swine farmers.
• Ecoro-VAC (E. coli Pilus Vaccine) Bovine E. coli pilus vaccine for preventing calf scours, used in combination with Locovac vaccine for comprehensive protection in calves. Targeted at bovine farmers.
• H5-AINK (Avian Influenza + Newcastle Disease Vaccine) Combined vaccine for prevention of Highly Pathogenic Avian Influenza (H5N1 and H5N6) and Newcastle Disease infection in chickens. Targeted at poultry farmers.
• Neguvon Solution (네구본질액) - Ectoparasiticide Broad-spectrum ectoparasiticide and dermatological treatment for livestock used for scabies, mite infestations, ticks, fleas, and other external parasites. Targeted at livestock farmers.
• KRSL Rabies Neutralization Antibody Testing Service Rabies neutralization antibody testing service, officially certified by France's ANSES Nancy Laboratory (the WOAH reference laboratory for rabies) as a rabies neutralization antibody testing institution. Testing conducted twice weekly (Tuesday and Friday), results reported within ~2 weeks, certificates issued for international pet travel / export. Targeted at veterinary hospitals and pet owners exporting animals internationally.
• Veterinary Chemical Preparations, Antibiotics, Nutritional Supplements and Metabolic/Immune Enhancers Broad line of chemical preparations including antibiotics, antibacterial agents, nutritional supplements, and metabolic/immune enhancers for livestock, aquaculture, and companion animals, produced under KVGMP standards. Targeted at livestock farmers, aquaculture operators, companion animal owners, and veterinary hospitals.
• KML001 Anticancer Drug Candidate (Sodium Metaarsenite) Proprietary orally bioavailable arsenic compound (sodium metaarsenite) developed as an anticancer agent targeting telomeres and the catalytic subunit of telomerase (hTERT). Has undergone Phase I clinical trials (published in Clinical Cancer Research 2008, 14(14):4593-4602) and multiple in vitro/in vivo studies in prostate cancer, non-Hodgkin's lymphoma, and solid tumors. Targeted at human oncology research and licensing partners.

Quantifiable outcome

• Rabies neutralization antibody testing capacity: testing conducted twice weekly (Tuesday and Friday), with results available within approximately 2 weeks of sample receipt
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• 8 Domestic Research Institutes (South Korea)coreStrategic or Co-development Partner · 1 January 1998Komipharm's R&D center established in 1998 has built a cooperative system with 8 domestic research institutes in South Korea, focusing on veterinary disease research and new product development including vaccine and anti-cancer drug development.
• 10 Overseas Research Institutes (America, Europe)coreStrategic or Co-development Partner · 1 January 1998Komipharm's R&D center has established cooperation with 10 overseas institutes in America and Europe for international new drug development, including vaccines and anti-cancer treatments, supporting the company's global bio-field leadership strategy.
• ANSES Nancy Laboratory (France)coreStrategic or Co-development PartnerANSES Nancy Laboratory, the World Animal Health Organization (WOAH) reference laboratory for rabies in France, officially certified Komipharm's KRSL (Rabies Serology Laboratory) as a rabies neutralization antibody testing institution. This certification enables KRSL to provide officially recognized rabies antibody testing for international pet travel.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Zoetis: World's largest animal health company offering vaccines, parasiticides, and diagnostics across livestock and companion animals. Directly comparable to Komipharm's core veterinary vaccine and pharmaceutical portfolio, but at materially greater global scale.
• Boehringer Ingelheim Animal Health: Major multinational animal health player with a strong livestock vaccine portfolio (including swine and avian influenza). Comparable to Komipharm in product categories, with broader global reach and pipeline depth.
• Merck Animal Health: Global animal health division of Merck offering vaccines, anti-infectives, and parasiticides across livestock and companion animals. Competes with Komipharm in swine, poultry, and bovine vaccine markets internationally.

Direct peers

• Virbac: Independent global animal health company focused on vaccines, parasiticides, and pharmaceuticals for livestock and companion animals. Closely comparable mid-sized animal health peer with similar product mix and emerging market presence.
• Ceva Santé Animale: Global veterinary pharmaceutical company specializing in vaccines and pharmaceuticals for swine, poultry, and ruminants. Highly comparable in product categories and geographic emphasis on emerging markets.
• Phibro Animal Health: Animal health and nutrition company focused on vaccines, parasiticides, and nutritional specialties for livestock. Comparable mid-tier competitor with similar livestock vaccine orientation.
• Vetoquinol: Independent veterinary pharmaceutical company offering vaccines and pharmaceuticals for livestock and companion animals. Comparable in size and product mix to Komipharm's animal health division.

Regional players

• Choong Ang Vaccine Laboratories: Korean veterinary vaccine manufacturer focused on livestock and companion animals. Direct domestic Korean competitor to Komipharm with overlapping product categories and customer base.
• KBNP (Korea BNP): Korean veterinary vaccine and animal health products manufacturer. Regional peer competing with Komipharm in the domestic Korean market with overlapping livestock vaccine offerings.

Emerging players

• IDEXX Laboratories: Leader in companion animal diagnostics and testing services. Comparable to Komipharm's KRSL diagnostic/testing franchise in offering certified animal disease diagnostics, though focused on companion animal in-clinic testing rather than rabies serology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Komipharm